Compare Crispr Therapeutics AG (CRSP) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Impinj Inc — how do they compare? Crispr Therapeutics AG trades at $53.8 (market cap $5.23B), while Impinj Inc trades at $179.24 (market cap $5.32B). The key difference: Crispr Therapeutics AG and Impinj Inc are close in size by market cap, and Impinj Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | PI | |
|---|---|---|
Market Cap | $5.23B | $5.32B |
Sector | Health | Technology |
52-Week High | $76.78 | $241.91 |
52-Week Low | $44.34 | $91.34 |
Enterprise Value | $3.65B | $5.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Impinj (PI) trades at $178.58, up 1.32% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying interest. The company reported record Q2 2026 revenue and earnings, beating estimates, but maintains negative net income margins. Analyst consensus is strongly bullish with a $186 price target, though high valuation multiples and insider sales present cautionary notes.
Outlook remains positive driven by RFID demand growth and sequential earnings beats, but risks include profitability challenges, high debt-to-asset ratio, and competitive pressures. The stock's current price near consensus target suggests limited upside without further fundamental improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
